Racing rising resistance, Novartis marches malaria therapy into phase 3

Novartis and the non-profit Medicines for Malaria Venture (MMV) have hit go on the phase 3 development of a novel combination therapy, hustling the solid dispersion formulation toward the final R&D hurdle on the strength of evidence it may kill drug-resistant forms of the parasite.